Apomorphine: an underutilized therapy for Parkinson's disease (Q34048141)

30 July 2017

1 reference

title

Apomorphine: an underutilized therapy for Parkinson's disease (English)

1 reference

30 July 2017

1 reference

1 reference

1

Poewe W

1 reference

30 July 2017

Wenning GK

2

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 September 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

15

1 reference

30 July 2017

issue

5

1 reference

30 July 2017

page(s)

789-794

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C789%3A%3AAID-MDS1005%3E3.0.CO%3B2-H

30 July 2017

1 reference

Treatment of Parkinson's disease with aporphines. Possible role of growth hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C789%3A%3AAID-MDS1005%3E3.0.CO%3B2-H

THERAPEUTIC EFFICACY OF APOMORPHINE COMBINED WITH AN EXTRACEREBRAL INHIBITOR OF DOPAMINE RECEPTORS IN PARKINSON'S DISEASE

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C789%3A%3AAID-MDS1005%3E3.0.CO%3B2-H

On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C789%3A%3AAID-MDS1005%3E3.0.CO%3B2-H

Apomorphine protects against MPTP-induced neurotoxicity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C789%3A%3AAID-MDS1005%3E3.0.CO%3B2-H

SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN ON-OFF OSCILLATIONS

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C789%3A%3AAID-MDS1005%3E3.0.CO%3B2-H

Subcutaneous apomorphine in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C789%3A%3AAID-MDS1005%3E3.0.CO%3B2-H

Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C789%3A%3AAID-MDS1005%3E3.0.CO%3B2-H

Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C789%3A%3AAID-MDS1005%3E3.0.CO%3B2-H

Apomorphine-induced penile erections in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C789%3A%3AAID-MDS1005%3E3.0.CO%3B2-H

Injected apomorphine and orally administered levodopa in Parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C789%3A%3AAID-MDS1005%3E3.0.CO%3B2-H

Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C789%3A%3AAID-MDS1005%3E3.0.CO%3B2-H

Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C789%3A%3AAID-MDS1005%3E3.0.CO%3B2-H

Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C789%3A%3AAID-MDS1005%3E3.0.CO%3B2-H

Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C789%3A%3AAID-MDS1005%3E3.0.CO%3B2-H

Comparison of motor response to apomorphine and levodopa in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C789%3A%3AAID-MDS1005%3E3.0.CO%3B2-H

Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C789%3A%3AAID-MDS1005%3E3.0.CO%3B2-H

Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C789%3A%3AAID-MDS1005%3E3.0.CO%3B2-H

Cabergoline in Parkinson's disease complicated by motor fluctuations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C789%3A%3AAID-MDS1005%3E3.0.CO%3B2-H

Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C789%3A%3AAID-MDS1005%3E3.0.CO%3B2-H

Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200009%2915%3A5%3C789%3A%3AAID-MDS1005%3E3.0.CO%3B2-H

10.1002/1531-8257(200009)15:5<789::AID-MDS1005>3.0.CO;2-H

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference